Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Potassium Flux in Hemodialysis Patients

4 janvier 2021 mis à jour par: Frank O'Brien, Washington University School of Medicine

The Effect of Intra-dialytic Potassium and Magnesium Fluctuations on Cardiovascular Functioning in ESRD Patients Undergoing In Center Hemodialysis

Current practice of outpatient hemodialysis entails prescription of standard electrolyte concentrations based upon patient prescription history and monthly serum electrolyte measurements. Dialysate concentration of potassium can be adjusted based on standard available concentrations including 2mmol/L and 3mmol/L. Standard available dialysate concentration of Magnesium is 0.5mmol/L (which is not ordinarily adjusted further). Potassium and Magnesium are not routinely measured before or after each dialysis, therefore serum levels are largely unknown outside of once monthly measurements.

This study aims to further study this correlation of electrolyte fluctuations (potassium and magnesium) and cardiac arrhythmias/heart rate variability in the ESRD population.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

This is a prospective, cross-sectional study utilizing a study population at Chromalloy American Kidney Center, an outpatient dialysis unit, which currently serves approximately 150 End Stage Renal Disease (ESRD) patients.

After enrollment, patients will be provided with a schedule for data collection. A standard 12-lead ECG will be performed.A small non-invasive device (MyPatch Holter monitor) will be attached to each patient's chest before their first weekly dialysis session to measure heart rhythm and arrhythmia generation. After the recorder is attached, a standard set of bedside autonomic function tests will be administered. These tests include standing from supine position, hand grip, Valsalva maneuver and deep breathing.Changes in heart rate, heart rhythm, and blood pressure in response to these maneuvers will be assessed. The holter monitor will be worn for the next 92-96 hours and removed after completion of their regular third weekly dialysis session (Friday or Saturday). The data from these holter monitors will be analyzed by the Heart Rate Variability Lab at Washington Univeristy. No modifications to the Holter monitor devices will be made for this study.

Patient vital signs pre/intra/post dialysis by standard protocol will be obtained, including the following parameters: blood pressure, heart rate, oxygen saturation, relative blood volume/hematocrit, dialysate flow rate, blood flow rate, ultrafiltration volume.Participant serum sodium, chloride, potassium, blood urea nitrogen, and magnesium immediately prior to and after dialysis session will be measured. Participant serum potassium and magnesium levels every 30 minutes for the first 2 hours of the first weekly dialysis session will be measured by taking 1mL of blood from the dialysis circuit. Effluent dialysate, which contains no blood or cellular components, will be collected concurrently with serum sample analysis every 30 minutes during the first weekly dialysis session by taking 10mL of fluid from the dialysate drain line to be analyzed for sodium, chloride, and potassium. Serum potassium levels will also be measured immediately prior to and after second and third weekly dialysis sessions by taking 1mL of blood from dialysis circuit. The capability to draw blood from the dialysis circuit/tubing has already been incorporated as an industry standard and no modifications to standard dialysis circuit will be made. This will ensure that the patient will not have any needle sticks to obtain necessary samples. Obtained serum samples will subsequently be coded and sent to the Core Lab for Clinical Studies (CLCS) at Washington University for processing and destruction there after.

All specimens will be assigned a de-identified study code that will be stored in a secure/locked location separate from collected data. All clinical data obtained will be de-identified and entered into a datasheet on a Washington University secure encrypted server. In addition, the Washington University in St. Louis School of Medicine Institute for Informatics, Informatics Core Services (ICS) will be used for centralized management and processing of collected data. Washington University in St. Louis belongs to a consortium of institutional partners that work to maintain a software toolset and workflow for electronic collection and management of research and clinical trial data. The Research Electronic Data Capture (REDCap) system will be utilized for data collection and processing in our study. The REDCap servers are securely housed in an on-site limited access data center managed by the Research Infrastructure Services at Washington University. All web-based information and transmission are encrypted with storage on a private, firewall protected network.

Data collected by Holter monitors and serum electrolyte measurements will subsequently be analyzed by the research team.

Participation in this study will not interfere with regularly scheduled thrice weekly dialysis treatments and clinic workflow. Nor will participation in this study result in modification of previously prescribed treatment.

Type d'étude

Observationnel

Inscription (Réel)

25

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Missouri
      • Saint Louis, Missouri, États-Unis, 63110
        • Washington Univeristy in St Louis

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Eligible patients based on a limited chart review from the Chromalloy American Kidney Center population will be recruited. These will all be on in center hemodialysis three times per week. Eligible patients based on inclusion/exclusion criteria as listed above will be randomly selected by a random number generator. If selected, they will be invited to participate in the study.

La description

Inclusion Criteria:

  • Age >18 years
  • Consistent thrice weekly in center hemodialysis as defined as no missed sessions in the last 30 days.
  • Goal Kt/V Urea (>1.2, which suggests adequate dialysis based on KDOQI guidelines) for at least 3 months
  • Serum potassium 3.5-8.0 mEq/L
  • Hemoglobin of >8.0g/dL

Exclusion Criteria:

  • Age <18 years
  • Evidence of residual renal function as defined by >100mL of urine output per day
  • Those whom do not have capacity to consent
  • Change in dialysis prescription within the past 30 days
  • 12-lead ECG shows non-sinus cardiac rhythm (atrial fibrillation, atrial flutter, or paced rhythm)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To examine and better define the correlation between electrolyte fluctuations, arrhythmia generation, and heart rate variability contributing to cardiovascular morbidity/mortality as described in previous retrospective observational studies.
Délai: 1 year
This study aims to assess if there is a correlation between serum electrolyte changes and abnormal heart rhythms or heart rate variability
1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

21 mai 2019

Achèvement primaire (Réel)

30 novembre 2020

Achèvement de l'étude (Réel)

30 novembre 2020

Dates d'inscription aux études

Première soumission

24 février 2020

Première soumission répondant aux critères de contrôle qualité

24 février 2020

Première publication (Réel)

27 février 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 janvier 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 janvier 2021

Dernière vérification

1 janvier 2021

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 201901179

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

No sharing planned

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

3
S'abonner